6 résultats
FIELD OF THE INVENTION
The present invention is directed to a dietary supplement for treatment of behavioral problems in canines and seizures in canines and felines and, more particularly, to a dietary supplement which includes taurine in a liquid lecithin base.
BACKGROUND OF THE INVENTION
Taurine
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to pending U.S. application Ser. No. 14/561,091 entitled "Transdermal Cannabinoid Formulations", filed Dec. 4, 2014, now U.S. Pat. No. 9,375,417, issued Jun. 28, 2016, the disclosure of which is hereby incorporated by reference
BACKGROUND
The clinical usefulness of the cannabinoids, including 11.sup.9-tetrahydrocannabinol (/1.sup.9-THC), to provide analgesia, help alleviate nausea and emesis, as well as stimulate appetite has been well-recognized. Cannabinoids offer a variety of pharmacological benefits, including, but not
BACKGROUND
The clinical usefulness of the cannabinoids, including .DELTA..sup.9-tetrahydrocannabinol (.DELTA..sup.9-THC), to provide analgesia, help alleviate nausea and emesis, as well as stimulate appetite has been well-recognized. Cannabinoids offer a variety of pharmacological benefits,
FIELD OF THE INVENTION
The present invention is directed to pharmaceutical compositions for transmucosal delivery of biologically active agents. More particularly, this invention relates to a novel method for controlling and promoting the rate and extent of transmucosal permeation and absorption of
FIELD OF THE INVENTION
The present invention is directed to pharmaceutical compositions for transmucosal delivery of biologically active agents. More particularly, this invention relates to a novel method for controlling and promoting the rate and extent of transmucosal permeation and absorption of